Investigation on the Duration of Extended Adjuvant Letrozole treatment.
Recruiting
- Conditions
- breast cancer, post-menopausal, aromatase inhibitor, letrozole, extended hormonal therapymamma carcinoom, aromatase remmer, verlengde hormonale therapie
- Registration Number
- NL-OMON23112
- Lead Sponsor
- eiden University Medical Center (LUMC)
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1823
Inclusion Criteria
1. Postmenopausal at the time of randomization;
2. Histologically proven invasive breast cancer (stage I, II, or III) adequately treated at the time of diagnosis;
Exclusion Criteria
1. ER and PgR negative or unknown primary tumors;
2. Evidence of previous or current localized or distant breast cancer recurrence;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease free survival (DFS).
- Secondary Outcome Measures
Name Time Method 1. Overall survival;<br /><br>2. Distant disease free survival;<br /><br>3. Contralateral breast cancer;<br /><br>4. Safety.